Quick Answer
Amylyx Pharmaceuticals, Inc. reported Total Assets of $332.64 million for fiscal year 2025.
Amylyx Pharmaceuticals, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $332.64M | +71.8% |
| 2024 | $193.63M | -62.6% |
| 2023 | $517.45M | +32.2% |
| 2022 | $391.45M | +270.6% |
| 2021 | $105.61M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $362.74M | +44.7% | +86.4% |
| June 30, 2025 | $194.60M | -41.4% | -11.4% |
| March 31, 2025 | $219.68M | -47.4% | +13.4% |
| December 31, 2024 | $193.63M | -62.6% | -22.8% |
| September 30, 2024 | $250.71M | -46.3% | -24.5% |
| June 30, 2024 | $332.16M | -26.8% | -20.4% |
| March 31, 2024 | $417.46M | +2.3% | -19.3% |
| December 31, 2023 | $517.45M | +32.2% | +10.9% |
- Amylyx Pharmaceuticals, Inc. showed an increase of +71.8% in Total Assets compared to the prior fiscal year.
- Over the 2021–2025 period, Amylyx Pharmaceuticals, Inc.’s total assets has grown by 215.0% (from $105.61 million to $332.64 million).
- The most recent figure is from Amylyx Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: